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Abstract
Background: Penicillium marneffei is a dimorphic fungus endemic in Southeast Asia. It can cause fatal penicilliosis in
humans, particularly in HIV-infected people. Diagnosis of this infection is difficult because its clinical manifestations are not
distinctive. Specialized laboratory tests are necessary to establish a definitive diagnosis for successful management. We have
demonstrated previously that a cell wall mannoprotein Mp1p, abundant in P. marneffei, is a potential biomarker for
diagnosis of P. marneffei infections. In the present study, we describe immunoassays based on Mp1p derived from the yeast
Pichia pastoris expression system.
Methodology/Principal Findings: We generated monoclonal antibodies (MAbs) and rabbit polyclonal antibodies (PAbs)
against Mp1p expressed in P. pastoris. Subsequently, we developed two Mp1p antigen capture ELISAs which employed
MAbs for both the capture and detecting antibodies (MAb-MAb pair) or PAbs and MAbs as the capture and detecting
antibodies (PAbs-MAb pair) respectively. The two Mp1p antigen ELISAs detected Mp1p specifically in cultures of P. marneffei
yeast phase at 37–40uC and had no cross-reaction with other tested pathogenic fungi. The sensitivities and specificities of
the two antigen assays were found to be 55% (11/20) and 99.6% (538/540) for MAb-MAb Mp1p ELISA, and 75% (15/20) and
99.4% (537/540) for PAbs-MAb Mp1p ELISA performed using 20 sera with culture-confirmed penicilliosis, and 540 control
sera from 15 other mycosis patients and 525 healthy donors. Meanwhile, we also developed an anti-Mp1p IgG antibody
ELISA with an evaluated sensitivity of 30% (6/20) and a specificity of 98.5% (532/540) using the same sera. Furthermore,
combining the results of Mp1p antigen and antibody detection improved the sensitivity of diagnosis to 100% (20/20).
Conclusions/Significance: Simultaneous detection of antigen and antibody using the immunoassays based on Mp1p
derived from P. pastoris greatly improves detection sensitivity. The procedures should be useful for the routine diagnosis of
penicilliosis.
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Introduction
Penicillium marneffei is an emerging fungus endemic in Southeast
Asian regions, including Burma, Cambodia, Indonesia, Malaysia,
Thailand, Vietnam, and southern parts of China [1,2]. Penicilli-
osis, the systemic disease caused by P. marneffei, occurs in both
immunocompetent and immunocompromised patients, particu-
larly in AIDS patients. The infection mainly affects HIV-infected
patients and is considered to be one of the most common
opportunistic infections among AIDS patients in the endemic
regions, and is therefore regarded as an indicator disease for AIDS
[3,4]. In addition, infections by P. marneffei have been reported in
visitors who had travelled to the endemic regions [4].
Penicilliosis is a disseminated and progressive disease with high
mortality. However, successful therapeutic management has been
hampered by an absence of rapid and accurate diagnosis due to its
non-specific symptoms and similar biological characteristics to other
common pathogenic fungi, such as Histoplasma capsulatum, Cryptococ-
cus neoformans and various Aspergillus species [5,6]. A number of
diagnostic methods based on antibody as well as antigen detection
have been developed [7,8,9,10], but they have not been used for
routine diagnosis. The antibody tests were developed using crude
extracts of fungal antigen and the inherent batch-to-batch variation
makes these tests not amenable to standardization. Our aim was to
develop the assays using antibodies against pure antigen that would
show improved sensitivity and specificity. We have previously
cloned a gene that encodes Mp1p, a cell wall antigenic
mannoprotein that is abundant in both yeast and mycelia phases
of P. marneffei [11]. By using the polyclonal antibodies (PAbs) raised
against recombinant Mp1p (rMp1p) protein expressed in E. coli, we
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established an ELISA-based antibody and antigen assay for
diagnosis of P. marneffei infections [12,13]. To establish more
sensitive diagnostic methods, in the present study we produced
Mp1p protein using the Pichia pastoris expression system, which may
provide the necessary post-translational modifications, such as
glycosylation, to produce a protein that may be structurally closer to
its native form [14]. Next, we generated both monoclonal antibodies
(MAbs) and rabbit PAbs against P. pastoris derived Mp1p. We also
developed two optimal Mp1p antigen capture ELISA assays which
employed only MAbs, or PAbs and MAb as the capture and
detecting antibodies respectively. Furthermore, we developed an
ELISA-based antibody assay with rMp1p derived from P. pastoris.
The feasibility of using simultaneous Mp1p antigen and antibody
detection by the P. pastoris derivedMp1p based assays in diagnosis of
penicilliosis is discussed.
Materials and Methods
Ethics Statement
The use of patient serum samples was approved by Institutional
Review Board of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster under protocol no. UW 04-278 T/600
for all samples collected since September 2004. Control sera were
collected specifically for this study. Informed written consent was
obtained from each subject. The use of control sera obtained from
blood donors and patient sera from an already-existing collection
was approved by the Ethics Committee of the Zhujiang Hospital
of Southern Medical University, Guangzhou, China, with the
following reference number: ZJYY-2010-YXJYZX-001.
Clinical specimens and Strains
Twenty serum specimens were obtained from 14 penicilliosis
patients diagnosed by positive culture from blood or bone marrow
aspirate specimens, of which 3 specimens from 2 patients were co-
infected with Cryptococcus neoformans. Six of the 14 patients had 2
consecutive sera which were collected every three days. Sera were
collected from patients with other fungal diseases, including seven
with invasive aspergillosis, four with systemic candidiasis, two with
pulmonary pseudallescheriasis and two with pulmonary aspergil-
loma. All patients with invasive aspergillosis had underlying
haematological malignancy and multilobar pulmonary involve-
ment with multiple positive smears and cultures from bronchoal-
veolar lavage fluid or sputum specimens. In addition, four cases
were confirmed by histology from biopsy or postmortem
examination. All patients with systemic candidiasis were neutro-
penic and had positive blood cultures. Pulmonary aspergilloma
was diagnosed by positive culture from sputum or lung tissue and
histopathology of resected lung tissue. The 525 negative control
serum specimens were obtained from blood donors who were
healthy at the time of participation.
A P. marneffei PM4 strain, Aspergillus spp. (A. fumigatus, A. flavus, A.
terreus, and A. niger), and C. neoformans were obtained from the
Department of Microbiology, University of Hong Kong. Candida
spp. (C. albicans, C. glabrata, C. tropicalis, C. krusei, and C. parapsilosis)
were obtained from the Research Centre for Medical Mycology,
Beijing University, China [15].
The fungal culture filtrates from different growth conditions
were prepared as described previously [11,12,15]. P. marneffei was
first cultured on Sabouraud agar plates (Guangzhou Letongtai
Biotech Co., Ltd, China) at 37uC or 28uC for 7 to 10 days. Culture
supernatants were obtained by inoculating fungal cells from plates
into RPMI-1640 (GIBCO, Carlsbad, CA). Cultures were shaken
at 40uC, 37uC or 28uC for 5 to 6 days, centrifuged at 5000 rpm for
20 min, passed through a 0.45-mm-pore-size filter (Corning Inc.,
N.Y.) and stored at 280uC until used.
Expression of rMp1p in Pichia pastoris
The Mp1p gene encoding a secreted cell wall mannoprotein in
P. marneffei was characterized in a previous study [11]. To acquire
a soluble protein, the N-terminal cleavable signal peptide and the
C-terminal cleavable glycosylphosphatidylinositol (GPI) domain
were removed from the full-length Mp1p gene and cloned into the
P. pastoris expression vector pPIC9K (Invitrogen, Carlsbad, CA)
[11]. The truncated Mp1p gene in P. pastoris strain GS115
(Invitrogen) was expressed and identified according to manufac-
turer’s instructions. A large scale expression of recombinant Mp1p
protein (rMp1p) was optimized and the protein was purified by Ni-
nitrilotriacetic acid affinity chromatography (Qiagen, Hilden,
Germany). The purity of rMp1p was assessed by sodium dodecyl
sulfate-polyacrylamide gels (SDS-PAGE) and western blotting as
described previously [15]. In brief, the purified rMp1p was
separated electrophoretically in a 12.5% gel and transferred to a
nitrocellulose membrane. After blocking with 3% BSA (Sigma-
Aldrich), the membrane was incubated with anti-serum from
guinea pigs immunized with purified rMp1p from E.coli [11] and
anti-His monoclonal antibodies for 1 h at 37uC. After washing, the
membrane was incubated with horseradish peroxidase (HRP;
Sigma-Aldrich) conjugated goat anti-rabbit and goat anti-mouse
antibody for 30 min at 37uC, and developed by incubation with
Amersham ECL Advance Western Blotting Detection Kit (GE
Healthcare, Fairfield, CT). The concentration of purified rMp1p
was determined by using the Bicinchoninic Acid Protein Assay Kit
(Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s
instructions.
Preparation of MAbs and PAbs against Mp1p
The process of preparation and identification of MAbs against
Mp1p was described in our previous study [15,16]. In brief,
BALB/c mice were immunized intradermally with 50 mg of
purified rMp1p emusified with Freund’s adjuvant (Sigma-Aldrich)
at ten-day intervals for 8 weeks followed by intravenously
administered boosters for three days before fusion. Antibodies
specific for P. marneffei in the hybridoma cell culture supernatant
were screened by indirect ELISA using rMp1p and indirect
immunofluorescent staining (IFA) using slides with immobilized
fungal cells killed in 3.7% formalin solution overnight at 4uC. The
isotypes of the MAbs were determined using a commercially
available mouse MAb isotyping kit (Zymed Laboratories, Carls-
bad, CA). MAbs were purified from ascitic fluid by ammonium
sulfate precipitation and were conjugated with biotin using the EZ-
LinkH Sulfo-NHS-Biotinylation Kit following the manufacturer’s
instructions (Pierce Biotechnology, Rockford, IL). Rabbit poly-
clonal antibodies (PAbs) against rMp1p were produced in New
Zealand White rabbits. Rabbits were immunized subcutaneously
with 500 mg of purified rMp1p emulsified with Freund’s adjuvant
(Sigma-Aldrich) at ten-day intervals for 8 weeks followed by
intravenous boosters for three days before collection of serum. The
IgG fraction was purified by protein A column chromatography
(GE Healthcare, Chalfont St. Giles, United Kingdom) and the
purified MAbs and PAbs specific for P. marneffei were identified by
IFA as described previously [15].
Identification of MAb epitope groups by competitive
ELISA
The epitopes groups of the MAbs were analyzed by competitive
ELISA as described previously [16] with rMp1p as the coating
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antigen. Microwell plates (Costar, Corning, N.Y.) were coated
with 100 ml/well of rMp1p at a concentration of 1 mg/ml in
carbonate-bicarbonate (pH 9.6) coating buffer overnight at 4uC.
Afterwards, the wells were blocked with 3% BSA in phosphate
buffered saline for 2 h, and then a constant concentration of one of
the non-biotinylated MAbs (50 ml) was incubated with an optimal
concentration of different biotinylated MAbs (50 ml) for 1 h at
26uC. After the plates were washed, streptavidin-HRP (Sigma-
Aldrich) was added and plates were incubated for 30 min at 26uC.
The plates were washed, and the binding of the biotinylated MAb
was detected by the addition of tetramethylbenzidine (TMB)
substrate (KPL, Gaithersburg, MD). The reaction was stopped
after 10 min by the addition of 1 N sulfuric acid, and the plates
then were examined in an ELISA plate reader (Bio-Tek, Winooski,
VT). An unlabeled MAb specific for dengue virus serotype 2
nonstructural protein 1 [16] was used as irrelevant control. The
distinct binding epitopes of MAbs were determined as described
previously [16].
Development of Mp1p antigen capture ELISAs
The procedure for the optimal antigen capture ELISA was
carried out as described previously with modifications [16]. In
brief, microwell plates (Costar, Corning) were coated with 100 ml/
well of capture antibodies (MAb or PAbs) overnight at 4uC
followed by incubation with a blocking reagent containing 2.5 g
Casein sodium salt, 1.21 g Tris-base, 2 g gelatin, 20 g sucrose,
0.2 g Merthiolate, and 5 ml Tween20 in 1000 ml dH2O (Sigma-
Aldrich). After removal of the blocking solution, 100 ml of of
culture filtrates of various fungal pathogens serially diluted or
human sera diluted 1:10 in 0.1% BSA were added per well and
incubated at 37uC for 1 h. After the plates were washed,
biotinylated MAb (100 ml/well) was added and incubated for
30 min at 26uC. Following incubation with streptavidin-HRP
(Sigma-Aldrich), TMB substrate was added. The reaction was
stopped after 10 min by the addition of 0.3 N sulfuric acid, and
the plates were then examined in an ELISA plate reader (Bio-Tek)
at 450 nm.
Development of indirect Mp1p antibody ELISA
Microwell plates (Costar, Corning) were coated with 10 ng of
rMp1p in a total volume of 100 ml/well overnight at 4uC followed
by incubation with a blocking regent (the same as mentioned in
Mp1p antigen capture ELISAs). After removal of the blocking
solution, 100 ml/well of human sera diluted 1:100 with 0.1% BSA
were added, and incubated for 1 h at 37uC. After washing,
100 ml/well of goat anti-human IgG-HRP (Sigma-Aldrich) diluted
1:8000 and TMB substrate was added. The reaction was stopped
after 10 min by the addition of 0.3 N sulfuric acid and absorbance
was determined as described above.
Statistical analysis
The categorical variables between the two antigen ELISA
methods and each combined antigen ELISA/anti-Mp1p IgG
ELISA methods were compared using McNemar test.
Results
Expression of Mp1p in P. pastoris and production of
Mp1p-specific MAbs and PAbs
We have previously described the production of PAbs and
MAbs against the rMp1p derived from E. coli [11,17]. In this
study, rMp1p was produced in a yeast protein expression system.
To achieve protein secretion, a truncated form of the Mp1p gene,
where the N-terminal cleavable signal peptide and C-terminal GPI
membrane attachment signal sequence were removed [11], and
then the Mp1p gene was cloned downstream of the a-factor
secretion domain in the P. pastoris vector pPIC9K. As shown in
Figure 1, rMp1p was abundantly secreted in culture superna-
tants, and the size was consistent with the expected size of 50 kDa
(Figure 1, A). Western blotting analysis of rMp1p with serum
from guinea pigs immunized with E.coli derived rMp1p [11] and
anti-His MAb demonstrated the immunoreactivity of the rMp1p
expressed from P. pastoris (Figure 1, B).
Figure 1. SDS-PAGE (A) and Western blotting (B) analysis of
rMp1p expressed in Pichia pastoris. (A) M: protein molecular-mass
marker; Lane 1: purified rMp1p; Lane 2 to 4: induced supernatant of
positive transformant (pPIC9K-Mp1p/GS115) at 3, 4 and 5 days,
respectively; Lane 5: induced supernatant of control transformant
(pPIC9K/GS115); (B) Lane 1: the serum from a guinea pig immunized
with rMp1p from E.coli; Lane 2: the serum from guinea pigs pre-
immunization; Lane 3: irrelevant MAb control; Lane 4: anti-His MAb.
doi:10.1371/journal.pone.0028796.g001
Table 1. The Characteristics of 18 anti-Mp1p MAbs.
MAb Epitopea Isotype ELISAb Reactivity with P. marneffei (IFA)
Yeast phase Mycelia phase
M8 I IgG ++ + 2
M4 II IgG1 +++ + 2
M14 III IgG1 ++ + 2
M1 IV IgG1 +++ + 2
M2 IV IgG1 +++ + 2
M3 IV IgG1 +++ + 2
M5 IV IgG1 +++ + 2
M6 IV IgG1 +++ + 2
M7 IV IgG2a +++ + 2
M9 IV IgG2b +++ + 2
M10 IV IgG1 ++ + 2
M11 IV IgG2a +++ + 2
M12 IV IgG2b +++ + 2
M13 IV IgG1 ++ + 2
M15 IV IgG + + 2
M16 IV IgG1 ++ + 2
M17 IV IgG2a ++ + 2
M18 IV IgG2b ++ + 2
aThe competition ELISA was performed to analyze the epitope groups of the
different MAbs. Eighteen MAbs were found to fall into four groups, with each
group reacting with the same epitope or sterical overlapping epitopes on
Mp1p. The experiment was repeated with similar results.
bThe purified rMp1p were used as the coating antigen and reacted with cell
supernatants of hybridomas secreted anti-Mp1p MAbs. The absorbance was
measured at 450 nm: +: OD450 = 1–1.5; ++: OD450 = 1.5–2; +++: OD450.2.
doi:10.1371/journal.pone.0028796.t001
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We prepared anti-rMp1p PAbs and 18 anti-rMp1p MAbs by
using the rMp1p derived from P. pastoris to immunize rabbits and
mice respectively. MAbs specific for Mp1p were selected according
to a strong positive ELISA reaction with rMp1p and further
confirmed by IFA with a strong positive reaction to P. marneffei cells
in yeast phase. The specificities of the MAbs and PAbs were
identified to be exclusively specific for P. marneffei cells in yeast
phase with no reactivity to P. marneffei cells in mycelia phase and
other fungi.
In order to develop a MAb-MAb ELISA to detect Mp1p, we
need to identify two MAbs that bind to different epitopes.
Competitive ELISA of all possible pairs of MAbs was employed
to determine the epitope specificity of these MAbs using rMp1p
as the coating antigen. While most of the MAbs recognized a
common epitope (IV), at least four different epitopes on the
Mp1p, were identified as determined by the inhibition of
different MAbs (Table 1). The above results indicate that these
MAbs or MAb/PAbs combinations can be useful for develop-
ment of two-site sandwich antigen capture assays for detection of
P. marneffei.
Specificity and sensitivity of the Mp1p antigen ELISAs in
detection of rMp1p and fungal culture filtrates
To establish MAb-MAb ELISA or PAbs-MAb ELISA for
detection of Mp1p in P. marneffei, all possible pairs of MAbs or
MAb/PAbs were tested to select the optimal capturer-detector,
based on the sensitivity in detection of both rMp1p and native
Mp1p in culture filtrates of P. marneffei in yeast phase. From these
studies MAb M4 and M12 (Table 1) were selected as capture and
detecting antibody for the MAb-MAb pair, and PAbs with M8 for
the PAbs-MAb pair. The MAb-MAb Mp1p ELISA was more
sensitive than the PAbs-MAb Mp1p ELISA with a detection limit
of 7.8 pg/ml rMp1p, while the lower limit of the PAbs-MAb
Mp1p ELISA was approximately 62.5 pg/ml. However, the
MAb-MAb Mp1p ELISA was less sensitive than PAbs-MAb
Mp1p ELISA when culture filtrates from the yeast phase of P.
marneffei cells were used (Figure 2, A; B).
Next, we further analyzed for cross-reactivity of the two Mp1p
ELISAs with other related and opportunistic fungi. Only filtrates
of identically inoculated P. marneffei yeast phase cell cultures at
37uC or 40uC gave positive signals (Figure 2, C; D). In addition,
the culture at 37uC had higher OD450 values than those cultured
at 40uC, which may due to more Mp1p being secreted at normal
body temperature (37uC) than during fever (40uC) or different
modifications of Mp1p at different temperature. It is interesting
that both Mp1p antigen assays failed to detect Mp1p in cultures of
mycelia phase at 28uC. Finally, none of the other fungal cultures
gave positive results, demonstrating that the two Mp1p assays were
specific for the detection of P. marneffei cells in yeast phase, the only
form existing in humans, with no cross-reaction to the other tested
common pathogenic fungi.
Figure 2. Evaluation of the sensitivity and specificity of two Mp1p antigen ELISAs. (A, B): evaluation of the sensitivity by detection of
rMp1p and natural Mp1p in P. marneffei cells in yeast phase cultured at 37uC by two Mp1p antigen ELISAs; (C, D): evaluation of the specificity by
detection of Mp1p in kinds of fungal cultured filtrates by MAb-MAb Mp1p ELISA (C) and PAbs-MAb Mp1p ELISA (D). The positive OD450 values are
restricted to cultured filtrate of P. marneffei in yeast phase, and are higher when cultured at 37uC.
doi:10.1371/journal.pone.0028796.g002
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Evaluation of the two Mp1p antigen ELISAs and anti-
Mp1p antibody ELISA in positive detection of penicilliosis
patient sera
Our previous study [12] showed the improved sensitivity of
combination detection strategies involving Mp1p and Mp1p-
specific antibody. This encouraged us to apply a similar protocol
using the anti-Mp1p IgG antibody ELISA with rMp1p derived
from P. pastoris. The baseline of the two Mp1p antigen ELISAs and
of the anti-Mp1p IgG ELISA was determined by using serum
samples from 525 healthy donors. All serum samples were
analyzed by the two Mp1p antigen ELISAs at 1:10 dilution and
by the anti-Mp1p IgG ELISA at 1:100 dilution. The cutoff values
were determined as the mean OD450 value of negative controls
plus 5-times the standard deviation [16], yielding values of 0.317,
0.208, and 0.511 for the MAb-MAb, PAbs-MAb Mp1p ELISAs,
and anti-Mp1p IgG ELISA respectively. If a sample yielded an
OD450 value above the cutoff value of these assays, the result was
considered positive. Next, a panel of patient sera was used to
evaluate these assays. Of 20 sera obtained from 14 penicilliosis
patients, in which 3 specimens from 2 patients were co-infected
with C. neoformans, 11 (55%) and 15 (75%) sera at 1:10 dilution
were positive for Mp1p antigen as detected by MAb-MAb Mp1p
ELISA and PAbs-MAb Mp1p ELISA, respectively, while 6 (30%)
sera at 1:100 dilution were positive for Mp1p-specific IgG
antibody ELISA. It is interesting that the two samples from
Table 2. Results of Mp1p antigen and Mp1p specific IgG in patient sera by two Mp1p antigen ELISAs and an Mp1p antibody ELISA.
Patient No./Diagnosis OD450 values and results (+/2)
MAb-MAb Mp1p ELISA PAbs-MAb Mp1p ELISA Mp1p IgG ELISA
1/Penicilliosis 0.102 (2) 0.099 (2) 0.818 (+)
2/Penicilliosis 0.095 (2) 0.140 (2) 1.998 (+)
0.100 (2) 0.109 (2) 1.524 (+)
3/Penicilliosis 0.899 (+) 4.000 (+) 0.078 (2)
2.087 (+) 3.889 (+) 0.084 (2)
4/Penicilliosis 0.557 (+) 1.935 (+) 0.796 (+)
0.261 (2) 0.447 (+) 0.342 (2)
5/Penicilliosis 0.114 (2) 0.643 (+) 0.089 (2)
6/Penicilliosis 0.105 (2) 0.138 (2) 1.891 (+)
7/Penicilliosis 3.991 (+) 4.000 (+) 0.084 (2)
8/Penicilliosis 0.108 (2) 0.321 (+) 0.068 (2)
0.138 (2) 0.315 (+) 0.115 (2)
9/Penicilliosis 3.989 (+) 4.000 (+) 0.163 (2)
10/Penicilliosis 0.102 (2) 0.099 (2) 1.285 (+)
11/Penicilliosis 4.000 (+) 4.000 (+) 0.108 (2)
4.000 (+) 4.000 (+) 0.074 (2)
12/Penicilliosis 1.275 (+) 4.000 (+) 0.134 (2)
13/Penicilliosisa 0.832 (+) 3.103 (+) 0.061 (2)
14/Penicilliosisa 4.000 (+) 4.000 (+) 0.094 (2)
3.995 (+) 4.000 (+) 0.098 (2)
15/Invasive aspergillosis 0.110 (2) 0.141 (2) 0.096 (2)
16/Invasive aspergillosis 0.079 (2) 0.109 (2) 0.095 (2)
17/Invasive aspergillosis 0.112 (2) 0.112 (2) 0.099 (2)
18/Invasive aspergillosis 0.109 (2) 0.098 (2) 0.193 (2)
19/Invasive aspergillosis 0.130 (2) 0.104 (2) 1.048 (+)
20/Invasive aspergillosis 0.094 (2) 0.090 (2) 0.167 (2)
21/Invasive aspergillosis 0.099 (2) 0.094 (2) 0.052 (2)
22/COPD/aspergillosis 0.089 (2) 0.121 (2) 1.111 (+)
23/Bronchiectasis/aspergillosis 0.092 (2) 0.120 (2) 0.325 (2)
24/Invasive candidiasis 0.102 (2) 0.102 (2) 1.748 (+)
25/Invasive candidiasis 0.096 (2) 0.098 (2) 0.115 (2)
26/Invasive candidiasis 0.095 (2) 0.101 (2) 0.795 (+)
27/Invasive candidiasis 0.108 (2) 0.101 (2) 0.739 (+)
28/Pseudallescheriasis 0.094 (2) 0.176 (2) 0.163 (2)
29/Pseudallescheriasis 0.096 (2) 0.228 (+) 0.060 (2)
apenicilliosis patients co-infected with C. neoformans.
doi:10.1371/journal.pone.0028796.t002
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patient 4 were obtained before and after treatment with anti-
fungal drug, and the results showed a large decrease in antigen,
showing the efficacy of the treatment. Although the IgG ELISA
alone has almost no diagnostic value, the results in 19 of 20
penicilliosis patient sera are complementary to those from the
antigen tests, suggesting that the antibodies are successful in
sequestering the antigen.
Fifteen serum samples from other mycosis patients were tested
for Mp1p antigen, with only one pseudallescheriasis patient
sample yielding a weak positive by PAbs-MAb Mp1p ELISA.
Interestingly, of these 15 non-penicilliosis patients, 5 (33.3%)
patients (2 with aspergillosis and 3 with candidiasis) were positive
for Mp1p-specific IgG by anti-Mp1p IgG ELISA. The detailed test
information regarding these patients is summarized in Table 2.
Although patients 13 and 14 were co-infected with C. neoformans,
the positive results obtained for these patients were likely due to
penicilliosis since C. neoformans extracts in vitro were shown to be
negative in Figure 2. Again, the IgG ELISA alone has little
diagnostic value with 6/15 false positive. In this case it seems likely
that the IgG is recognizing an antigen common to several fungal
pathogens, although an authentic antibody response due to
environmental exposure cannot be ruled out.
The overall diagnostic accuracy of Mp1p antigen and antibody
ELISA for the identification of penicilliosis is summarized in
Table 3. The specificities of these assays were 99.6% (538/540),
99.4% (537/540), and 98.5% (532/540) for MAb-MAb Mp1p
ELISA, PAbs-MAb Mp1p ELISA, and anti-Mp1p IgG ELISA,
respectively, as determined using 540 controls including 15
patients with non-penicilliosis mycoses and 525 healthy volunteers.
When a combined detection strategy using both Mp1p antigen-
and antibody-based ELISA was used for the diagnosis of
penicilliosis, the sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were 85.0%, 98.1%,
63.0%, and 99.4% for MAb-MAb Mp1p/anti-Mp1p IgG ELISA,
and 100%, 98.0%, 64.5%, and 100% for PAbs-MAb Mp1p/anti-
Mp1p IgG ELISA, respectively.
Discussion
We have demonstrated previously that a cell wall mannopro-
tein, Mp1p, abundant in P. marneffei, is a potential biomarker for
serodiagnosis of active P. marneffei infections [11,12,13]. This
report describes the production of a panel of MAbs and PAbs
against P. pastoris-derived Mp1p that were used to develop two
Mp1p antigen capture ELISAs, one by using MAbs as both the
capture and detecting antibodies, and the other by using PAbs and
MAb as the respective capture and detecting antibodies. The
MAb-MAb Mp1p ELISA displayed an 8-fold higher rate of
detection compared to that of the PAbs-MAb Mp1p ELISA when
rMp1p was used as the target, but a 2-fold drop in sensitivity
compared to the PAbs-MAb Mp1p ELISA when applied to
culture filtrates. This may be due to differences in epitope
exposure between P. pastoris-expressed rMp1p and native Mp1p in
culture filtrates, or variation in Mp1p antigenicity between
different P. marneffei isolates. Furthermore, the ELISA results using
patient sera showed that the PAbs-MAb Mp1p ELISA was more
sensitive (75%) than MAb-MAb Mp1p ELISA (55%), indicating
that PAbs, when used as the capture antibody, may widen the
spectrum of natural epitopes, found within fungal proteins.
Mp1p is a highly antigenic cell wall mannoprotein that can elicit
an antibody response in infected patients [11,12,13]. Previous
studies investigating the detection of anti-Mp1p antibodies by the
E. coli BL21 derived rMp1p-based ELISA yielded a sensitivity of
80% and a specificity of 100% in penicilliosis patients [13],
providing a proof-of-concept for the serodiagnostic value of Mp1p.
In this study, we found that only 30% of penicilliosis patients were
positive for anti-Mp1p antibodies by the P. pastoris expressed
rMp1p based ELISA. This phenomenon of differential antibody
response in penicilliosis patients is probably related to patients with
different degrees of immunosuppression, who may produce low or
undetectable levels of antibodies [13,18]. It would have been
interesting to test our assays on the same samples that were used
previously to better characterize the improved value of the
method. Unfortunately, those original samples are no longer
available. We also found that there were cross-reactive anti-Mp1p
antibodies in aspergillosis and candidiasis patients. Possibly, these
patients had been infected with P. marneffei previously. Another
explanation is that rMp1p derived from recombinant P. pastoris,
may be highly mannosylated, and have cross-reactive epitopes
with other fungal proteins. However, in this study, the antibodies
raised against rMp1p recognized P. marneffei epitopes exclusively,
as demonstrated both by ELISA and by IFA. The epitope-specific
MAbs-based Mp1p antigen assay therefore displayed a high
specificity in penicilliosis patients. A weak positive result was
obtained with one sample from a patient with pseudallescheriasis
by PAbs-MAb Mp1p ELISA, which suggested that cross-reactivity
may exist between the Mp1p of P. marneffei and Pseudallescheria boydii
or other Scedosporium spp., such as S. apiospermum and S. prolificans.
Future studies may be performed to test for potential cross-
reactivity using more pathogenic fungal species such as P. boydii.
Table 3. Performance of Mp1p antigen and antibody ELISAs for diagnosis of Penicilliosis.
Mp1p antigen and
antibody assaysa Clinical samples, No. of positive/No. of sera (%) Overall diagnostic characteristic (%, n=560), (95% CI)
Penicilliosis
(n =20)
Other fungal
diseases (n=15)
Normal sera
(n =525) Sensitivity Specificity PPV NPV
1. MAb-MAb Mp1p ELISA 11/20 (55.0) 0/15 (0.0) 2/525 (0.4) 55.0 (31.0–77.0) 99.6 (99.1–100) 84.6 (55.0–98.0) 98.4 (97.3–99.5)
2. PAbs-MAb Mp1p ELISA 15/20 (75.0) 1/15 (6.7) 2/525 (0.4) 75.0 (51.0–91.0) 99.4 (98.7–100) 83.3 (59.0–96.0) 99.1 (98.3–99.9)
3. Mp1p antibody ELISA 6/20 (30.0) 5/15 (33.3) 3/525 (0.6) 30.0 (12.0–54.0) 98.5 (97.5–99.5) 42.9 (18.0–71.0) 97.4 (96.1–98.7)
4. MAb-MAb Mp1p ELISA
Plus Mp1p antibody ELISA
17/20 (85.0) 5/15 (33.3) 5/525 (1.0) 85.0 (62.0–97.0) 98.1 (97.0–99.2) 63.0 (42.0–81.0) 99.4 (99.0–99.7)
5. PAbs-MAb Mp1p ELISA
plus Mp1p antibody ELISA
20/20 (100) 6/15 (40.0) 5/525 (1.0) 100 (83.0–100) 98.0 (96.8–99.2) 64.5 (49.0–83.0) 100 (97.5–100)
aThere was no significant difference (McNemar test, P.0.1, n = 560) comparing assay 1 versus 2, or 4 versus 5. There were very significant differences (McNemar test,
P,0.005, n = 560) comparing assay 1 versus 4, and 2 versus 5.
doi:10.1371/journal.pone.0028796.t003
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When the PAbs raised against P. pastoris derived rMp1p were used
as the capture antibodies and MAb as a detector to form the two-
site sandwich antigen capture assay, the assay appears to have a
higher sensitivity (75%) than previous Mp1p antigen assays that
made use of two different PAbs raised against E. coli derived
rMp1p (sensitivity of 65.4%) [12]. Strikingly, combining the results
of the yeast P. pastoris derived Mp1p-based ELISA assays, we
found that in 95% (19/20) of the penicilliosis specimens, the
antigen test and the antibody test results are complementary to
each other, with only 1 of 20 serum specimens having
concomitantly significant Mp1p antigen and Mp1p antibodies.
The value of complementation of results targeting the Mp1p
antigen and anti-Mp1p antibodies was shown by the fact that
when the results of both tests were combined, the diagnostic
sensitivity increased to 100% in penicilliosis patients. However,
evaluation of the actual sensitivity and specificity of the assays in
prospective studies with a larger number of specimens from
patients with P. marneffei infection and other fungal diseases is
necessary.
In conclusion, this study describes the yeast P. pastoris derived P.
marneffei Mp1p-based antigen and antibody tests for diagnosis of
penicilliosis patients. The combined performances of Mp1p
antigen and antibody testing facilitate enhanced diagnosis rates
in P. marneffei infections. The procedures should be useful for the
routine diagnosis of penicilliosis.
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